Oxford BioMedica plc (OXB) Insider Lorenzo Tallarigo Buys 30,861 Shares of Stock
Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 30,861 shares of the company’s stock in a transaction that occurred on Thursday, November 23rd. The stock was bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,777.49 ($3,653.15).
Lorenzo Tallarigo also recently made the following trade(s):
- On Monday, October 23rd, Lorenzo Tallarigo purchased 30,436 shares of Oxford BioMedica plc stock. The stock was bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,739.24 ($3,602.84).
- On Friday, September 22nd, Lorenzo Tallarigo purchased 29,685 shares of Oxford BioMedica plc stock. The stock was bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,671.65 ($3,513.94).
Shares of Oxford BioMedica plc (LON:OXB) opened at GBX 8.55 ($0.11) on Friday. Oxford BioMedica plc has a 1-year low of GBX 3.31 ($0.04) and a 1-year high of GBX 11.25 ($0.15).
OXB has been the subject of several recent research reports. N+1 Singer lifted their price target on Oxford BioMedica plc from GBX 8.70 ($0.11) to GBX 10.20 ($0.13) and gave the stock a “hold” rating in a research report on Thursday, August 31st. Peel Hunt restated a “buy” rating and set a GBX 13 ($0.17) target price on shares of Oxford BioMedica plc in a research report on Tuesday, October 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a report on Thursday, August 31st.
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.